Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
New Drug Delivery across the Blood–Brain Barrier Volume II
share announcement

New Drug Delivery across the Blood–Brain Barrier Volume II

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: closed (31 January 2022) | Viewed by 6595

Special Issue Editor

Prof. Dr. Xavier Declèves

E-Mail Website
Guest Editor
Faculté de pharmacie, Université de Paris, UMR-S 1144, 4, Avenue de l’Observatoire, 75006 Paris, France
Interests: CNS interfaces; blood–brain barrier; neuropsychopharmacology; drug transporters; drug metabolism; pharmacokinetics; physiologically-based pharmacokinetics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Drug delivery into the central nervous system (CNS) is modulated by blood–brain interfaces. The blood–brain barrier (BBB), the blood–cerebrospinal fluid barrier (BCSFB), and the blood–arachnoid barrier (BAB) are key interfaces regulating the exchange of substances between the blood, the CSF, and the brain parenchyma. Drug delivery to the CNS can thus be limited due to unfavorable physicochemical properties, efficient active brain to blood carrier-mediated efflux, and/or poor active blood to brain carrier-mediated influx. Several strategies are currently developed to increase CNS drug delivery of small and large molecular weight drugs, including direct administration into the brain parenchyma, methods disrupting BBB integrity, development of specific chemicals or antisense oligonucleotides inhibiting efflux transporter activity, rational drug design decreasing substrate recognition by efflux transporters and/or increasing transport by influx transporters or carrier-mediated transcytosis receptors, and development of nanomedicines and biologics from microbiological origin targeting the BBB and delivering drugs into the brain parenchyma.

Prof. Dr. Xavier Declèves
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • blood–brain barrier
  • brain interfaces
  • drug delivery
  • neuropharmacology
  • drug transporters
  • nanomedicine

Related Special Issue

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

15 pages, 1287 KiB  
Review
Permeation Challenges of Drugs for Treatment of Neurological Tuberculosis and HIV and the Application of Magneto-Electric Nanoparticle Drug Delivery Systems
by Sinaye Mhambi, David Fisher, Moise B. Tchoula Tchokonte and Admire Dube
Pharmaceutics 2021, 13(9), 1479; https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics13091479 - 15 Sep 2021
Cited by 6 | Viewed by 2827
Abstract
The anatomical structure of the brain at the blood–brain barrier (BBB) creates a limitation for the movement of drugs into the central nervous system (CNS). Drug delivery facilitated by magneto-electric nanoparticles (MENs) is a relatively new non-invasive approach for the delivery of drugs [...] Read more.
The anatomical structure of the brain at the blood–brain barrier (BBB) creates a limitation for the movement of drugs into the central nervous system (CNS). Drug delivery facilitated by magneto-electric nanoparticles (MENs) is a relatively new non-invasive approach for the delivery of drugs into the CNS. These nanoparticles (NPs) can create localized transient changes in the permeability of the cells of the BBB by inducing electroporation. MENs can be applied to deliver antiretrovirals and antibiotics towards the treatment of human immunodeficiency virus (HIV) and tuberculosis (TB) infections in the CNS. This review focuses on the drug permeation challenges and reviews the application of MENs for drug delivery for these diseases. We conclude that MENs are promising systems for effective CNS drug delivery and treatment for these diseases, however, further pre-clinical and clinical studies are required to achieve translation of this approach to the clinic. Full article
(This article belongs to the Special Issue New Drug Delivery across the Blood–Brain Barrier Volume II)
►▼ Show Figures

Figure 1

16 pages, 573 KiB  
Review
Brain Metastasis Treatment: The Place of Tyrosine Kinase Inhibitors and How to Facilitate Their Diffusion across the Blood–Brain Barrier
by Eurydice Angeli and Guilhem Bousquet
Pharmaceutics 2021, 13(9), 1446; https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics13091446 - 10 Sep 2021
Cited by 12 | Viewed by 2814
Abstract
The incidence of brain metastases has been increasing constantly for the last 20 years, because of better control of metastases outside the brain, and the failure of most drugs to cross the blood–brain barrier at relevant pharmacological concentrations. Recent advances in the molecular [...] Read more.
The incidence of brain metastases has been increasing constantly for the last 20 years, because of better control of metastases outside the brain, and the failure of most drugs to cross the blood–brain barrier at relevant pharmacological concentrations. Recent advances in the molecular biology of cancer have led to the identification of numerous molecular alterations, some of them targetable with the development of specific targeted therapies, including tyrosine kinase inhibitors. In this narrative review, we set out to describe the state-of-the-art in the use of tyrosine kinase inhibitors for the treatment of melanoma, lung cancer, and breast cancer brain metastases. We also report preclinical and clinical pharmacological data on brain exposure to tyrosine kinase inhibitors after oral administration and describe the most recent advances liable to facilitate their penetration of the blood–brain barrier at relevant concentrations and limit their physiological efflux. Full article
(This article belongs to the Special Issue New Drug Delivery across the Blood–Brain Barrier Volume II)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop